Valeant Shares May Hit the Rocks
6 mins. to read
…and so may activist investor Bill Ackman. Short-seller turned activist investor Bill Ackman has just recorded a $2 billion write-down on his portfolio due to a failed bet on the Canadian drugmaker Valeant Pharmaceuticals. But he promises to fight back, as he still believes he can build value in the company. In the 13F form…